Shiyao Group Co., Ltd. was founded in May 1938. It is one of the earliest pharmaceutical companies established by our party and army. It has made great contributions to the victory of the War of Resistance Against Japan, the War of Liberation, and the medical and health care cause of the socialist New China. Shiyao Group has a total assets of 15 billion yuan and more than 20,000 employees. It is the first super-large pharmaceutical enterprise established in the pharmaceutical industry in the country through a strong joint method, and is also one of the large-scale pillar enterprise groups in Hebei Province.

Shi Pharmaceutical Group has six major business segments, and more than 30 subsidiaries including Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Yinhu Pharmaceutical, etc., are located in Hebei, Tianjin, Ji, Jin, Liao, Shandong, Inner Mongolia and Hong Kong. Among them, the holding subsidiary located in Hong Kong, China Pharmaceutical Group Co., Ltd. is the first overseas listed company in the Chinese pharmaceutical industry. It is currently one of the largest pharmaceutical listed companies in Hong Kong and one of the constituent stocks of the Hong Kong Hang Seng Red Chip Stock Index. It has been rated as one of the 100 outstanding listed companies with a turnover of less than US$1 billion by the world-renowned Forbes magazine for two consecutive times.

Shiyao Group is mainly engaged in the development, production and sales of pharmaceutical products. The products mainly include nearly a thousand varieties, including seven series, including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system medication, respiratory system medication and Chinese patent medicine. At present, the annual production capacity of eight products including vitamin C, penicillin, amoxicillin, caffeine, 7-ACA ranks first in the world. The annual production capacity of Shiyao Group's preparation products is 3 billion powder injections, 20 billion tablets, 8 billion capsules, and 1 billion soft capsules. The output, scale and strength of the leading products of Shiyao Group rank among the best in the country, and has developed into one of China's largest "chemical raw materials production base" and "comprehensive preparation production base". Currently, Shiyao Group has 30 products with single products sold over 100 million yuan, and its product sales are spread across the country and more than 60 countries and regions in the world.

Over the past ten years since its establishment, Shijiao Group has been continuously pioneering and innovating with the strong support of all sectors of society, and has achieved continuous, healthy and rapid development, and has achieved gratifying results. The company's comprehensive strength has always been at the forefront of the Chinese pharmaceutical industry. It has successively won honorary titles such as the National Medical System Advanced Collective, Quality-Efficient Advanced Enterprise, Product Quality Relief Commitment Unit, National May 1st Labor Certificate, China Environmental Protection Enterprise Charity Award and other honorary titles. In 2010, the group's sales revenue reached 13.088 billion yuan, a year-on-year increase of 23%, ranking second among pharmaceutical industry enterprises in the country for four consecutive years; achieved profits and taxes of 1.605 billion yuan, a year-on-year increase of 10.22%; paid 730 million yuan of various taxes; exports earned US$550 million, a year-on-year increase of 22%, and the total export volume continued to rank first in the domestic pharmaceutical industry.

In terms of scientific research and development, Shijiao Group relies on the company's "postdoctoral research workstation", national enterprise technology center, "863 Plan" high-tech industrialization base and Hebei Provincial Preparation Engineering Technology Center, and has successively developed and developed new drugs in more than 110 national areas in recent years, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields. At present, Shiyao Group has applied for more than 220 patents, 116 have been authorized, 17 PCT international patents have been applied for, and has obtained authorization in 18 countries. Among them, the first-class new drug "Embipu" in the country with independent intellectual property rights is a global leading drug in the field of stroke treatment. It is the third national new drug in my country with independent intellectual property rights. It is protected by patents in 86 countries around the world. At present, the company has signed a patent use rights transfer agreement for Enbipu Soft Capsules in the European and American and Korean markets with two well-known companies, the United States and South Korea, setting a precedent for Chinese pharmaceutical companies to transfer drug intellectual property rights to the world's most developed countries, and won honors for the country and nation. In 2008, under the leadership of the Ministry of Science and Technology, the China Antibiotic Industry Technology Innovation Alliance was led by the establishment of the China Antibiotic Industry Technology Support Alliance and obtained project support from the National Science and Technology Support Plan. In the application for the national major science and technology project of "Major New Drug Creation", 1 innovative drug incubation base, 3 innovative drug research and development technology platforms and 6 new drug development projects have settled in Shiyao. In 2009, the Group's pharmaceutical preparation and drug release technology laboratory ranked among the "National Key Laboratory", and the "Butyphthalide Raw Materials and Soft Capsules" project won the second prize of the National Science and Technology Progress Award. The Group was jointly rated as a "National Innovation Enterprise" by the Ministry of Science and Technology, the State-owned Assets Supervision and Administration Commission of the State Council, and the All-China Federation of Trade Unions, marking that the Group's innovation system has entered a new stage of systematization and institutionalization.

In terms of product quality, Shijiao Group has established a complete three-level quality management system. All drugs have passed GMP certification, and all subordinate enterprises have passed ISO9000, OHSAS18000 and ISO14001 certifications. The product market inspection pass rate has always remained 100%. At the same time, the company uses technology to improve its quality connotation. Currently, 11 raw material products such as caffeine, vitamin C, vitamin B12, and amoxicillin have obtained EU COS certification. In May 2010, the group's oral solid preparation workshop, vitamin C and sodium vitamin C passed the US FDA certification with the highest quality standards in the world with "zero defects". It is the first domestic preparation manufacturer to pass the FDA certification using domestic equipment, and it is also the first company in Asia to produce online FDA certification, and has obtained a "pass" to enter the high-end pharmaceutical market in Europe and the United States.

In terms of brand building, Shiyao Group owns two "famous Chinese trademarks: "Shiyao" and "Ouyi"; after being evaluated by the World Brand Laboratory, one of the world's five major brand value evaluation institutions, the "Shiyao" brand has been selected as the "China's 500 Most Valuable Brands" for four consecutive years since 2005, and Shiyao Group has ranked among the top 500 Chinese companies for three consecutive times.

In terms of fulfilling social responsibilities, Shiyao Group is always at the forefront and always enthusiastically supports social welfare undertakings. Shiyao is always indispensable in activities such as SARS, Indonesian tsunami, Wenchuan earthquake, Yushu earthquake, medical care for children with serious illnesses, volunteer services, and visits to old areas. Shiyao Group has been constantly giving back to the society with real things. Since its establishment, it has invested more than 60 million yuan in public welfare undertakings.

Looking forward to the future, Shiyao People will continue to uphold the corporate philosophy of "making good medicines for China", be committed to the cause of human health, contribute to the society with more, newer and better drugs, and strive to build Shiyao Group into a top-class domestic and top 30 pharmaceutical companies in the world.